[18F]F-DED PET imaging of reactive astrogliosis in neurodegenerative diseases: preclinical proof of concept and first-in-human data

Table 2 Overview of the demographics of human subjects included in this study

Diagnosis	Age (years)	Gender	Disease duration (years)	[¹⁸F]F-DED dose (MBq)	Height (cm)	Body weight (kg)	Disease severity indices
MCI Alzheimer’s pathologic change (A + T − N −)	69	M	0.5	190	170	69	MMSE: 26/30
AD-Dementia (A + T + N +)	66	F	2.0	169	163	52	MMSE: 21/30
PD (1.7 y disease duration)	55	F	1.7	180	165	62	UPDRS III: 14; MoCA: 28/30
PD (4.8 y disease duration)	56	F	4.8	149	167	64	UPDRS III: 18; H&Y: 1; MoCA: 29/30
Autoimmune encephalitis	53	M	25.2	217	182	72	–
MSA-C	56	M	2.1	162	190	84	UPDRS III: 30; H&Y: 2; MoCA: 28/30
MSA-P	65	M	4.2	134	173	96	UPDRS III: 19; MoCA: 29/30
ODG	60	F	1.3	244	160	61	–
Healthy control	28	F	–	150	170	64	–

MCI mild cognitive impairment; AD Alzheimer’s disease, A β-amyloid; T tau; N neurodegeneration; PD Parkinson’s disease; MSA Multiple system atrophy; C cerebellar subtype; P parkinsonian subtype; ODG Oligodendroglioma; MMSE mini mental state examination; MoCA Montreal Cognitive Assessment; UPDRS Unified Parkinson’s Disease Rating Scale; H&Y Hoehn and Yahr scale

ISSN: 1742-2094